I think that the contents of this post need to be challenged.
And it is best to challenge with facts. This is from, The Lancet - one of the foremost, prestigious, respected and peer reviewed medical journals in the world. This is science and not blather.
CBD = cannabidiol
"These findings are promising, but a number of concerns must be addressed before CBD can enter routine clinical practice, and chief among them is safety. Although often touted as a natural product, CBD is a drug like any other and has associated side effects. In the three trials of childhood-onset, treatment-resistant epilepsy, adverse events were reported in 75% to 93% of participants. It is also unclear how CBD might interact with other drugs; evidence suggests that CBD increases serum concentration of several antiepileptic drugs, including valproate and clobazam and their active metabolites. This interaction might result in an overestimation of CBD efficacy in patients who are also receiving these drugs. Additionally, although CBD does not produce the psychoactive effects that are typically seen with other cannabinoids such as THC, no controlled studies in human beings regarding the potential physical dependence effects (eg, withdrawal and tolerance) of CBD have been reported. Without such data, it is impossible to understand its long-term effects."
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(18)30049-8/fulltext
- Forums
- ASX - By Stock
- CGB
- Bring on CGL
Bring on CGL, page-37
-
- There are more pages in this discussion • 77 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CGB (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
SPONSORED BY The Market Online